HOT STOCK

Biolidics shares sink 22% after calling off US sales of Covid-19 test kits

Singapore

BIOLIDICS shares sank 22 per cent on Monday after the Catalist-listed firm announced on Sunday that it had mutually agreed with Aytu BioScience to terminate a distribution agreement for its Covid-19 antibody test kits in the US, amid increased competition for such kits.

Attachments: